Related Experiment Video
Updated: Jun 16, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review
Sarah Hendee1, Gerald Falchook2
1HCA HealthONE, Sky Ridge Medical Center, Lone Tree, CO, USA.
None:
SMARCA4 is an ATPase subunit in the switch/sucrose non-fermentable complex (SWI/SNF), a chromatin-remodeling complex. SMARCA4 provides energy for the SWI/SNF complex to regulate gene expression through chromatin structural rearrangement and transcription regulation. In SMARCA4-deficient cancers, its paralog SMARCA2 is sometimes upregulated and can serve as a pharmacological target. Of the 20-25% of cancers identified to have a mutation in a gene encoding a protein for the SWI/SNF complex, 15% of these alterations include SMARCA4 alterations. Therefore, SMARCA4-directed therapies are under investigation in clinical trials and are a promising new strategy for treating patients with a SMARCA4-mutated cancer. Currently, all published clinical trials of SMARCA4-directed therapies are for orally bioavailable small-molecule inhibitors. Clinical trials without results include small-molecule inhibitors, monoclonal antibodies, and a bifunctional MabPair product. The aim of this literature review was to summarize the current SMARCA4-directed therapies in oncology clinical trials.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...